Assertio (ASRT) Set to Announce Quarterly Earnings on Monday

Assertio (NASDAQ:ASRT) will be issuing its quarterly earnings data after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Assertio (NASDAQ:ASRT) last issued its earnings results on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Assertio had a positive return on equity of 4.88% and a negative net margin of 261.08%. The business had revenue of $31.13 million for the quarter, compared to the consensus estimate of $30.37 million. During the same quarter in the previous year, the company earned $0.13 earnings per share. On average, analysts expect Assertio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Assertio Stock Down 15.8 %

Shares of Assertio stock opened at $0.85 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.93 and a quick ratio of 1.51. Assertio has a 1 year low of $0.73 and a 1 year high of $1.80. The firm’s 50-day moving average is $1.15 and its two-hundred day moving average is $1.17. The stock has a market cap of $81.04 million, a price-to-earnings ratio of -0.21 and a beta of 0.83.

Wall Street Analyst Weigh In

Separately, Maxim Group initiated coverage on shares of Assertio in a report on Friday, July 26th. They set a “buy” rating and a $3.00 target price on the stock. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Assertio currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.25.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.